LLL3 is used in the research of cancers with constitutive STAT3 activation; it inhibits STAT3 dimerization and phosphorylation, thereby blocking STAT3 nuclear translocation and STAT3-dependent gene expression (including Bcl-xL and cyclin D1); additionally, LLL3 induces growth inhibition and apoptosis via the caspase pathway in human breast cancer and rhabdomyosarcoma cells.